Symptom Burden and Survivorship Care for Patients With Prostate Cancer on Androgen Deprivation Therapy

被引:0
|
作者
Sentana-Lledo, Daniel [1 ]
Saraf, Anurag [2 ,3 ]
Morgans, Alicia K. [1 ]
机构
[1] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA
[3] Brigham & Womens Hosp, Boston, MA USA
来源
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2025年 / 23卷 / 01期
关键词
CARDIOVASCULAR-DISEASE; COGNITIVE FUNCTION; RADIATION-THERAPY; AMERICAN-SOCIETY; HORMONAL-THERAPY; BONE HEALTH; MEN; RISK; TESTOSTERONE; BICALUTAMIDE;
D O I
10.6004/jnccn.2024.7047
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer survivors represent a growing population of patients with a diagnosis of prostate cancer, whether they were cured using local therapies or continue to receive systemic treatment of advanced disease. Many patients receive androgen deprivation therapy (ADT) during treatment, which is associated with many long-lasting physical and psychological effects. Identifying and addressing the needs of survivors is imperative for improving their health and well-being. This narrative review highlights the most common issues associated with ADT affecting survivorship in prostate cancer, including cardiovascular and metabolic effects, musculoskeletal health, sexual morbidity, and local therapy effects, as well as the mental and psychological toll. A special emphasis is placed on the existing literature examining specific interventions to alleviate these symptoms, along with describing existing gaps in knowledge, with the goal of promoting dedicated studies aimed at enhancing the survivorship experience of patients with prostate cancer.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer
    Zhao, Sherry
    Urdaneta, Alfredo I.
    Anscher, Mitchell S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) : 929 - 942
  • [32] Factors impacting all-cause mortality in prostate cancer brachytherapy patients with or without androgen deprivation therapy
    Taira, Al V.
    Merrick, Gregory S.
    Galbreath, Robert W.
    Butler, Wayne M.
    Wallner, Kent E.
    BRACHYTHERAPY, 2010, 9 (01) : 42 - 49
  • [33] Falls in men on androgen deprivation therapy for prostate cancer
    Hussain, Shabbir
    Breunis, Henriette
    Timilshina, Narhari
    Alibhai, Shabbir M. H.
    JOURNAL OF GERIATRIC ONCOLOGY, 2010, 1 (01) : 32 - 39
  • [34] Androgen deprivation therapy for prostate cancer and risk of dementia
    Robinson, David
    Garmo, Hans
    Van Hemelrijck, Mieke
    Damber, Jan-Erik
    Bratt, Ola
    Holmberg, Lars
    Wahlund, Lars-Olof
    Stattin, Par
    Adolfsson, Jan
    BJU INTERNATIONAL, 2019, 124 (01) : 87 - 92
  • [35] Complications of Androgen Deprivation Therapy in Men With Prostate Cancer
    Patil, Tejas
    Bernard, Brandon
    ONCOLOGY-NEW YORK, 2018, 32 (09): : 470 - 475
  • [36] Androgen Deprivation Therapy and Cognitive Function in Prostate Cancer
    Kluger, Jonathan
    Roy, Alicia
    Chao, Herta H.
    CURRENT ONCOLOGY REPORTS, 2020, 22 (03)
  • [37] The Economic Burden of Prostate Cancer Survivorship Care
    Skolarus, Ted A.
    Zhang, Yun
    Miller, David C.
    Wei, John T.
    Hollenbeck, Brent K.
    JOURNAL OF UROLOGY, 2010, 184 (02): : 532 - 538
  • [38] Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Japanese Patients With Prostate Cancer
    Masuda, Hiroshi
    Fujimoto, Ayumi
    Kanesaka, Manato
    Hou, Kyokusin
    Suyama, Takahito
    Araki, Kazuhiro
    Kojima, Satoko
    Naya, Yukio
    ANTICANCER RESEARCH, 2021, 41 (09) : 4443 - 4446
  • [39] Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy
    Masuda, Hiroshi
    ANTICANCER RESEARCH, 2023, 43 (01) : 305 - 309
  • [40] Maintaining intimacy for prostate cancer patients on androgen deprivation therapy
    Wassersug, Richard J.
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2016, 10 (01) : 55 - 65